Drug intelligence / Profile preview

IN029

Development stage: Preclinical
Lead developer: Innorna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**IN029** is an investigational mRNA combination vaccine developed by Innorna for prevention of respiratory syncytial virus infection and human metapneumovirus infection. The candidate is intended to generate protective vaccine-mediated immune responses against both respiratory viral pathogens. Specific encoded antigens, mRNA constructs, formulation details, and route of administration have not been publicly disclosed. IN029 is in IND-enabling development.

Beyond the preview

Go deeper on IN029.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IN029.

Explore the full profile